JP2022517461A5 - - Google Patents
Info
- Publication number
- JP2022517461A5 JP2022517461A5 JP2021512883A JP2021512883A JP2022517461A5 JP 2022517461 A5 JP2022517461 A5 JP 2022517461A5 JP 2021512883 A JP2021512883 A JP 2021512883A JP 2021512883 A JP2021512883 A JP 2021512883A JP 2022517461 A5 JP2022517461 A5 JP 2022517461A5
- Authority
- JP
- Japan
- Prior art keywords
- csf
- hgm
- antibody
- pharmaceutical composition
- composition according
- Prior art date
Links
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862729043P | 2018-09-10 | 2018-09-10 | |
| US62/729,043 | 2018-09-10 | ||
| US16/149,346 US10870703B2 (en) | 2017-10-02 | 2018-10-02 | Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist |
| PCT/US2018/053933 WO2019070680A2 (en) | 2017-10-02 | 2018-10-02 | METHODS OF TREATING IMMUNOTHERAPY-RELATED TOXICITY USING GM-CSF ANTAGONIST |
| USPCT/US2018/053933 | 2018-10-02 | ||
| US16/149,346 | 2018-10-02 | ||
| US16/204,220 | 2018-11-29 | ||
| US16/204,220 US10899831B2 (en) | 2017-10-02 | 2018-11-29 | Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity |
| US16/248,762 US10927168B2 (en) | 2017-10-02 | 2019-01-15 | Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab |
| US16/248,762 | 2019-01-15 | ||
| US16/283,694 | 2019-02-22 | ||
| US16/283,694 US11130805B2 (en) | 2017-10-02 | 2019-02-22 | Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist |
| PCT/US2019/050494 WO2020055932A2 (en) | 2018-09-10 | 2019-09-10 | Methods of treating immunotherapy-related toxicity using a gm-csf antagonist |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022517461A JP2022517461A (ja) | 2022-03-09 |
| JPWO2020055932A5 JPWO2020055932A5 (https=) | 2022-09-21 |
| JP2022517461A5 true JP2022517461A5 (https=) | 2022-09-21 |
Family
ID=69778357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021512883A Pending JP2022517461A (ja) | 2018-09-10 | 2019-09-10 | Ｇｍ－ｃｓｆアンタゴニストを使用した免疫療法関連毒性の治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP3849572A4 (https=) |
| JP (1) | JP2022517461A (https=) |
| KR (1) | KR20210075090A (https=) |
| CN (1) | CN113164520A (https=) |
| AU (1) | AU2019340662A1 (https=) |
| BR (1) | BR112021004489A2 (https=) |
| CA (1) | CA3111804A1 (https=) |
| IL (1) | IL281243A (https=) |
| MX (1) | MX2021002856A (https=) |
| SG (1) | SG11202102317PA (https=) |
| WO (1) | WO2020055932A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240158467A1 (en) * | 2018-10-31 | 2024-05-16 | Humanigen, Inc. | Materials and methods for treating cancer |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| CN118949031A (zh) * | 2019-06-03 | 2024-11-15 | 基尼克萨制药股份有限公司 | 用gm-csf拮抗剂治疗癌症 |
| WO2021204649A1 (en) * | 2020-04-06 | 2021-10-14 | Glaxosmithkline Intellectual Property Development Limited | Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome |
| CN113402620B (zh) * | 2021-07-30 | 2021-12-10 | 中山大学 | 细胞因子联合嵌合抗原受体的融合蛋白及其应用 |
| CN116887856A (zh) * | 2022-01-20 | 2023-10-13 | 舒泰神（北京）生物制药股份有限公司 | 一种特异性地识别粒细胞-巨噬细胞集落刺激因子受体的抗体制剂及其应用 |
| CN114606237B (zh) * | 2022-05-11 | 2025-10-28 | 上海优替济生生物医药有限公司 | Gm-csf抑制剂及其用途 |
| CN119144563B (zh) * | 2023-11-24 | 2025-11-25 | 成都赛恩吉诺生物科技有限公司 | 表达gm-csf截短功能区片段的免疫工程细胞及应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8398972B2 (en) * | 2006-11-21 | 2013-03-19 | Kalobios Pharmaceuticals, Inc. | Methods of treating dementia using a GM-CSF antagonist |
| NZ588850A (en) * | 2008-04-28 | 2012-12-21 | Kalobios Pharmaceuticals Inc | Antibodies to granulocyte-macrophage colony-stimulating factor |
| LT4461308T (lt) * | 2012-07-13 | 2025-06-10 | The Trustees Of The University Of Pennsylvania | Car priešnavikinio aktyvumo toksiškumo valdymas |
| US20160024200A1 (en) * | 2013-03-14 | 2016-01-28 | John Schrader | Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof |
| WO2015066262A1 (en) * | 2013-11-04 | 2015-05-07 | Trustees Of Dartmouth College | Methods for preventing toxicity of adoptive cell therapy |
| US20190292246A1 (en) * | 2016-11-03 | 2019-09-26 | Juno Therapeutics, Inc. | Combination therapy of a cell based therapy and a microglia imhibitor |
| EP3691663A4 (en) * | 2017-10-02 | 2021-08-18 | Humanigen, Inc. | METHODS OF TREATMENT OF TOXICITY ASSOCIATED WITH IMMUNOTHERAPIES USING A GM-CSF ANTAGONIST |
| US10899831B2 (en) * | 2017-10-02 | 2021-01-26 | Humanigen, Inc. | Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity |
| JP7411578B2 (ja) * | 2018-06-01 | 2024-01-11 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | 癌を治療するための物質及び方法 |
-
2019
- 2019-09-10 SG SG11202102317PA patent/SG11202102317PA/en unknown
- 2019-09-10 MX MX2021002856A patent/MX2021002856A/es unknown
- 2019-09-10 KR KR1020217010585A patent/KR20210075090A/ko not_active Withdrawn
- 2019-09-10 JP JP2021512883A patent/JP2022517461A/ja active Pending
- 2019-09-10 AU AU2019340662A patent/AU2019340662A1/en active Pending
- 2019-09-10 CN CN201980073595.4A patent/CN113164520A/zh active Pending
- 2019-09-10 BR BR112021004489-2A patent/BR112021004489A2/pt not_active Application Discontinuation
- 2019-09-10 CA CA3111804A patent/CA3111804A1/en active Pending
- 2019-09-10 WO PCT/US2019/050494 patent/WO2020055932A2/en not_active Ceased
- 2019-09-10 EP EP19860890.3A patent/EP3849572A4/en active Pending
-
2021
- 2021-03-03 IL IL281243A patent/IL281243A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022517461A5 (https=) | ||
| US6969517B2 (en) | Recombinant tumor specific antibody and use thereof | |
| US12018084B2 (en) | Anti-CXCR2 antibodies and uses thereof | |
| US20250074965A1 (en) | Anti-ptk7 immune cell cancer therapy | |
| CN108409860B (zh) | 抗人白细胞介素-4受体α单克隆抗体、其制备方法和应用 | |
| JP7747367B2 (ja) | 抗ヒトｔｓｌｐモノクローナル抗体及びその使用 | |
| US10442863B2 (en) | Construct for the delivery of a molecule into the cytoplasm of a cell | |
| JP2014508511A5 (https=) | ||
| CN113164520A (zh) | 使用gm-csf拮抗剂治疗免疫疗法相关毒性的方法 | |
| Khorasanizadeh et al. | Efficacy and safety of benralizumab, a monoclonal antibody against IL-5Rα, in uncontrolled eosinophilic asthma | |
| JP2021505183A (ja) | ヒトｉｌ−５に結合するモノクローナル抗体、その製造方法および用途 | |
| US20220378829A1 (en) | Genetically engineered immune cells targeting cd70 for use in treating solid tumors | |
| JPWO2020055932A5 (https=) | ||
| JPWO2006046661A1 (ja) | インターロイキン−６阻害剤 | |
| Mok et al. | Non-TNF biologics and their biosimilars in rheumatoid arthritis | |
| JP7450710B2 (ja) | 抗ｐｄ－ｌ１抗体及びその製薬用途 | |
| CN116535509A (zh) | 抗CD79b抗体、其制备方法及其应用 | |
| TWI825131B (zh) | Htlv-1關聯性脊髓病(ham)之治療或預防劑、及ham之治療方法 | |
| CN115925940B (zh) | 特异性结合cd47的抗体、其重组溶瘤病毒及其用途 | |
| Matias | Drug interactions with therapeutic proteins | |
| AU2017254625B2 (en) | Functional plasticity of ILC2, immunity, and COPD | |
| WO2022225821A1 (en) | Methods of treating immunotherapy-related toxicity using a gm-csf antagonist | |
| Banić et al. | Intestinal Inflammation: Biologics and Small Molecules | |
| CN113929781A (zh) | 抗pd-1抗体及其稳定制剂 | |
| HK40034156A (en) | Cd38 protein antibody and application thereof |